Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: 2 | Rare Historical Photos

9 Startups Nobody Talks About That Are Flying Under the Radar—and Raking In Millions

While flashy unicorns like OpenAI and SpaceX dominate headlines, dozens of smaller startups are quietly turning profits and changing industries without the hype. These hidden players focus on niche markets, sustainable models, and loyal customers rather than viral buzz. Many are already generating millions annually while staying out of the…

Thousandaire

HIMS Stock Just Got Rocked (Again) By the FDA. This Analyst Still Thinks Hims & Hers Can Surge 50%.

Despite a sharp selloff after the latest FDA warning, Hims & Hers continues to post triple-digit annual gains and strong revenue growth, with at least one analyst projecting a 50% upside.

Barchart

Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy

Hims & Hers Health posted 73% revenue growth and 31% more subscribers in Q2. With analyst targets hitting $68, is now the time to buy HIMS?

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds

Oscar Health Inc (NYSE:OSCR) just became one of Wall Street's buzziest policy trades. With ACA (Affordable Care Act) subsidy chatter swirling ahead of a possible government shutdown, the tech-driven insurer is drawing Hims Hers Health Inc (NYSE:HIMS) style moonshot comparisons — and short sellers may be sitting on a powder…

Benzinga

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Benzinga

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy

Hims Hers Health Inc. (NYSE:HIMS) stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims Hers Health, dated Sept. 9, addressed to the company’s CEO, Andrew Dudum.

Benzinga

Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks

Food and Drug Administration Commissioner Martin Makary stated on Friday that Hims Hers Health Inc. (NYSE:HIMS) broke federal law with its Super Bowl commercial promoting weight-loss drugs.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers Bets On Hormonal Health To Revive Investor Confidence

Hims Hers Health Inc. (NYSE:HIMS) launched a new category in men’s health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.

Benzinga

Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire

Wall Street's most crowded shorts are starting to look like powder kegs. Rocket Companies Inc (NYSE:RKT), Oscar Health Inc (NYSE:OSCR), and Hims Hers Health Inc (NYSE:HIMS) are sitting at the top of the market's short-interest leaderboard, each with more than a quarter of their float sold short.

Benzinga

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Benzinga

Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets

The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.

MarketBeat

What's Going On With Hims & Hers Shares Today?

Hims Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after GoodRx Inc. (NASDAQ:GDRX) announced a collaboration with Novo Nordisk to provide discounted access to two of the most in-demand GLP-1 drugs, Ozempic and Wegovy.

Benzinga

Hims & Hers Stock Slips As FTC Probe Into Subscription Practices Resurfaces

Hims Hers Health Inc. (NYSE:HIMS) stock is trading lower following a media report revealing that the Federal Trade Commission (FTC) has been investigating the company’s business practices for over a year.

Benzinga

Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now

Hims Hers Health Inc. (NYSE:HIMS) has been one of 2025’s hottest telehealth stocks, nearly doubling in value year to date, but a deepening clash with Novo Nordisk A/S (NYSE:NVO) over compounded weight-loss drugs, and shifting FDA rules, has turned momentum into headwinds, sending shares sliding 10% in the past three…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Diagnosis: Hims & Hers' August Price Dip Is an Opportunity to Buy

Hims & Hers falls into a buying opportunity followng the Q2 release and guidance update but investors shouldn't rush to get in, wait for this market to bottom.

Benzinga

Hims & Hers Stock Is Trading Lower Tuesday: What's Going On?

Hims Hers Health, Inc. (NYSE:HIMS) stock is trading lower Tuesday after the company reported a second-quarter sales miss on Monday after the market closed.

Benzinga

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

Benzinga

Hims & Hers Health Stock Tumbles On Q2 Earnings As Revenue Comes Up Short, Company Sees 'Exciting Period Of Growth' Ahead

Hims Hers Health Inc (NYSE:HIMS) reported second-quarter earnings after the market close on Monday. Here’s a rundown of the report.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Will Hims & Hers Fall Along With Novo Nordisk?

Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming.

Benzinga

Hims & Hers Stock Up, Nearing All-Time High As Weight-Loss Giants Stumble

Shares of telehealth company Hims Hers Health Inc (NYSE:HIMS) are up Thursday afternoon, and at one point, approached a new all-time high. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.

Benzinga

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

Weight-loss drugmaker Novo Nordisk A/S (NYSE:NVO)’s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some trouble if it hadn’t ended its partnership with…

Benzinga

Hims & Hers Stock Could Rocket To Meme Stock Fame — If Short Sellers Feel The Squeeze

Hims Hers Health, Inc. (NYSE:HIMS) has seen a surge in retail investor interest, which positions it as one of the most high-profile candidates for the next “meme stock” rally.

Benzinga

What's Going On With Hims & Hers Stock Wednesday?

Hims Hers Health, Inc. (NYSE:HIMS) shares are trading 16% higher Wednesday, adding to gains of more than 35% over the past month. Here’s a look at what’s going on.

Benzinga

What's Going On With Hims & Hers Health Stock Today?

Hims Hers Health Inc (NYSE:HIMS) shares surged in early trading Wednesday before pulling back. The stock was still up marginally at last check after the company announced a planned Canadian expansion.

MarketBeat

Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback

Hims & Hers stock dipped after Novo Nordisk pulled back its partnership for a weight loss drug distribution, though that may not mean much.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

The Federal Trade Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.